Pharmacogenomics — Ready for Prime Time?

Publisher Website
Google Scholar
Abstract
It cannot be emphasized too strongly that treatment of each patient is a highly individualized matter.— FDA-approved labeling for warfarin (Coumadin) NDA 9-218/5-105Pharmacogenomics is receiving a great deal of attention in scientific circles and, increasingly, in the popular press because of the promise of personalized medicine. Short of being able to cure an illness or to prevent one, every clinician's dream is to offer patients a precisely targeted drug at a precisely calibrated dose to address a specific ailment — and to do so without wreaking havoc on the rest of the body. We have ample reason to . . .